That's not the analysis that we have discussed with COVAX or other partners. It really was a significant reliance on production from the Serum Institute of India, and then a very significant third wave that affected that country, which led to export restrictions.
It is worth stepping back a bit and recognizing that, since the fall, COVAX has had access to the supply that it required. As such, it has been able to ensure that it can play the part that we hoped it would for developing countries and other members.